Sabra Healthcare REIT (NASDAQ:SBRA) Announces Earnings Results

Sabra Healthcare REIT (NASDAQ:SBRA) posted its quarterly earnings data on Monday. The real estate investment trust reported $0.41 EPS for the quarter, topping the consensus estimate of $0.16 by $0.25, Zacks reports. Sabra Healthcare REIT had a return on equity of 2.34% and a net margin of 7.61%. The firm had revenue of $249.57 million for the quarter, compared to the consensus estimate of $236.64 million. During the same quarter last year, the company earned $0.38 earnings per share. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year.

Sabra Healthcare REIT Trading Down 0.1%

Shares of SBRA stock opened at $19.72 on Tuesday. The company’s 50-day moving average price is $19.86 and its 200-day moving average price is $19.96. Sabra Healthcare REIT has a twelve month low of $17.53 and a twelve month high of $22.77. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.95. The stock has a market cap of $5.04 billion, a price-to-earnings ratio of 75.85, a PEG ratio of 1.73 and a beta of 0.63.

Insider Activity at Sabra Healthcare REIT

In related news, CEO Richard Matros sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $20.83, for a total value of $4,166,000.00. Following the sale, the chief executive officer owned 1,657,686 shares of the company’s stock, valued at $34,529,599.38. This trade represents a 10.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Raymond James Financial raised Sabra Healthcare REIT from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 6th. Truist Financial boosted their target price on shares of Sabra Healthcare REIT from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Barclays cut their price target on shares of Sabra Healthcare REIT from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. UBS Group decreased their price objective on shares of Sabra Healthcare REIT from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Tuesday, October 13th. Finally, Robert W. Baird lifted their price objective on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, August 31st. Seven equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.